Alvine raises $21.5 million to advance coeliac disease candidate
This article was originally published in Scrip
Executive Summary
Alvine Pharmaceuticals of the US has raised $21.5 million in an extension of its series A round to fund the recently initiated Phase IIa trial of its lead compound ALV003 for the treatment of coeliac disease.